H.R. 8083: Allowing Greater Access to Safe and Effective Contraception Act
This bill, known as the Allowing Greater Access to Safe and Effective Contraception Act, proposes several measures aimed at enhancing the availability of oral contraceptives in the United States. Below are the key components of the bill:
1. Priority Review for Over-the-Counter Contraceptives
The bill directs the Secretary of Health and Human Services to prioritize the review of applications for oral contraceptive drugs intended for routine use. This includes:
- The supplemental application should not pertain to emergency contraceptives or drugs approved for induced abortion.
- If approved, the drug would not be restricted by certain regulations for individuals aged 18 and older.
2. Fee Waivers for Applications
The bill stipulates that the fees usually required for submitting a supplemental application that receives priority review will be waived. This is designed to facilitate easier access to the application process for drug manufacturers.
3. Over-the-Counter Availability
For individuals under the age of 18, contraceptive drugs that qualify for priority review will still be subject to existing laws regarding their availability following approval.
4. GAO Study on Federal Funding for Contraceptive Methods
Within one year of the bill's enactment, the Comptroller General of the United States is tasked with conducting a study and reporting to Congress on federal funding allocated for contraception. This includes exploring funding sources such as:
- Medicare
- Medicaid
- Indian Health Services
- Health Benefit Exchanges under the Affordable Care Act
- Federally-qualified health centers
- Title X programs under the Public Health Service Act
- Temporary assistance for needy families
- TRICARE program
The study aims to examine the financial resources available over the past 15 years for various aspects of contraception including reimbursement, inventory, training, and patient education.
Implementation Timeline
The provisions described in this bill will apply to applications submitted both before and after the bill is enacted, as long as they remain pending.
Relevant Companies
- PFE: Pfizer, Inc. may see an increase in demand for its contraceptive products.
- ABBV: AbbVie Inc. could experience changes related to its oral contraceptive offerings.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
4 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Mar. 25, 2026 | Introduced in House |
| Mar. 25, 2026 | Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Natural Resources, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
